Your session is about to expire
← Back to Search
Belzutifan for Advanced Cancers
Study Summary
This trial is testing a new drug, Belzutifan, for people with certain types of tumors. The goal is to see if it shrinks the tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am a male and agree to follow specific study conditions.I have been treated with a HIF-2α inhibitor before.My cancer has spread to other parts of my body.I am taking strong CYP3A4 inhibitors that I cannot stop during the study.I have not taken any colony-stimulating factors in the last 28 days.I am not pregnant or breastfeeding and meet the specific conditions.My advanced cancer cannot be removed by surgery or cured with treatment.You have been diagnosed with HIV.I have a history of hepatitis B or currently have hepatitis C.I am fully active or restricted in physically strenuous activity but can do light work.I have not used any experimental drugs or devices in the last 4 weeks.My side effects from previous cancer treatments are mild or gone.I can provide a sample of my tumor for testing.I am currently being treated for an infection.I have been diagnosed with pheochromocytoma or paraganglioma.My tumor is a type of aggressive neuroendocrine tumor not from the pancreas.I have a serious heart condition.My cancer has spread to my brain or its coverings.I had another type of cancer but have been cancer-free for 2 years after treatment.I have complications like bleeding or blockages that need emergency surgery.I need extra oxygen or my oxygen levels are often below 92%.My pancreatic neuroendocrine tumor cannot be treated with surgery, radiation, or other local therapies aimed at cure.I do not have VHL disease.I have received an organ or tissue transplant from another person.I haven't had cancer treatment like chemotherapy in the last 4 weeks.I cannot take pills by mouth or have a condition that affects drug absorption.My PPGL cannot be removed by surgery or cured with treatment.I have had local treatments or radiation within the last 4 weeks.My blood pressure is under control and I have PPGL.My organs are functioning well.I have had PRRT treatment for my pancreatic neuroendocrine tumor within the last 12 weeks.My pancreatic cancer has worsened after at least one treatment.I have a confirmed diagnosis of GIST based on tissue analysis.I have had MIBG therapy or similar treatment in the last 3 months.My pancreatic tumor is confirmed to be a low or intermediate grade neuroendocrine tumor.I have VHL disease with at least one tumor that can be measured.I have been diagnosed with VHL disease.
- Group 1: Belzutifan
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are being signed up for this experiment?
"That is correct, the trial is currently looking for participants. The listing on clinicaltrials.gov shows that the trial was posted on 8/12/2021 and edited on 11/9/2022. 13 different sites are being used to recruit the 232 patients needed for this study."
Are there other examples where Belzutifan has been used in medical research?
"There are currently 16 clinical trials studying Belzutifan's efficacy with 3 of them being in Phase 3. Although a majority of the research is based in Cardiff, Wales, there are 850 different locations conducting these studies."
Does this research break new ground?
"There are 16 ongoing clinical trials for Belzutifan in 370 cities and 44 countries. The earliest trial was held in 2016 and involved 120 patients. The study completed its Phase 1 drug approval stage and 1 additional study has been conducted since then."
Could you tell me how many different facilities are testing this new treatment?
"Currently, University of Texas MD Anderson Cancer Center (Site 0112), Icahn School of Medicine at Mount Sinai (Site 0123), Penn Medicine: University of Pennsylvania Health System-Heme/Onc (Site 0127) are enrolling patients for this study. There are also 13 other sites across the country participating in this trial."
What has Belzutifan been traditionally used to treat?
"Belzutifan has demonstrated efficacy in the treatment of malignant neoplasms, anemia, sickle cell, and von hippel lindau disease."
Has Belzutifan been cleared by the FDA?
"Since there is only preliminary data indicating that Belzutifan is safe for human use, it received a score of 2."
Are investigators still looking for volunteers for this research project?
"This study is still looking for participants, according to the most recent information on clinicaltrials.gov. The trial was first posted on 8/12/2021 and was last edited on 11/9/2022."
Share this study with friends
Copy Link
Messenger